

Fecha del CVA

07/12/2023

## Parte A. DATOS PERSONALES

|                          |                                              |                       |  |
|--------------------------|----------------------------------------------|-----------------------|--|
| Nombre *                 | Federico                                     |                       |  |
| Apellidos *              | Garcia Garcia                                |                       |  |
| Sexo *                   | Hombre                                       | Fecha de Nacimiento * |  |
| DNI/NIE/Pasaporte *      |                                              | Teléfono *            |  |
| URL Web                  |                                              |                       |  |
| Dirección Email          | fegarcia@ugr.es                              |                       |  |
| Identificador científico | Open Researcher and Contributor ID (ORCID) * | 0000-0001-7611-781X   |  |
|                          | Researcher ID                                |                       |  |
|                          | Scopus Author ID                             |                       |  |

\* Obligatorio

### A.1. Situación profesional actual

|                         |                                    |          |  |
|-------------------------|------------------------------------|----------|--|
| Puesto                  | Jefe de Servicio                   |          |  |
| Fecha inicio            | 2009                               |          |  |
| Organismo / Institución | Hospital Universitario San Cecilio |          |  |
| Departamento / Centro   | Microbiología / Microbiología      |          |  |
| País                    |                                    | Teléfono |  |
| Palabras clave          |                                    |          |  |

### A.3. Formación académica

| Grado/Master/Tesis                           | Universidad / País                     | Año  |
|----------------------------------------------|----------------------------------------|------|
| Experto en Gestión de Laboratorio Clínico    | Universidad Internacional de Andalucía | 2010 |
| Programa Oficial de Doctorado en Farmacia    | Universidad de Granada                 | 1992 |
| Especialista en Microbiología Clínica        | Ministerio de Sanidad y Consumo        | 1991 |
| Licenciado en Farmacia Orientación Sanitaria | Universidad de Granada                 | 1987 |

## Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Federico García is Doctor in Pharmacy. Specialist in Clinical Microbiology, Head of the Microbiology Service and Coordinator of the R+D+I Area of the Hospital Universitario Clínico San Cecilio. President of the SEIMC ([www.seimc.org](http://www.seimc.org)). Director of the Andalusian Strategic Plan for the Approach to Viral Hepatitis. Researcher in charge of the consolidated group MP-13 IBS-GRANADA and PI of a group of the CIBER of Infectious Diseases, CIBERINFEC. He is a guest lecturer in the Masters in Tissue Engineering and Advanced Therapies, and Advances in Microbiology Research at the University of Granada (UGR), having been a tutor to 15 Masters students. He has directed 17 Doctoral Theses and supervises 3 other doctoral students currently. He has received funding from the ISCIII, European programs, and private funding. He participates in several Human Resources Assessment Commissions of Fundación Progreso y salud, Junta de Andalucía. He has been president of the Andalusian Society of Clinical Microbiology (SAMPAC), and of the Group of Study of Hepatitis of the Spanish Society of Infectious Diseases and Clinical Microbiology (GEHEP-SEIMC). His group has led national research and participated in international collaborations in the field of resistance and the implementation of molecular epidemiology tools in HIV, and resistance to antivirals, in the implementation of diagnosis in a single step of hepatitis in Andalusia and Spain, and in the elimination in vulnerable populations in the field of hepatitis C. Currently part of the Technical Group on HCV Infection of the Ministry of Health, and participates in several international collaborations in hepatitis C (SHARED. Hepcare). He has lead the Spanish AIDS Research Network's Work Package of Resistors and Subtypes program 2 and is part of national and

European expert committees on HIV resistance, being a member of the Steering Committee of the European Society for Antiviral Resistance (ESAR). The group it leads contributes to several European organisations on resistance (ESAR, CORONET, HEPVIR) and participates in several studies and cohort programmes (ART-CC, SPREAD, COHERE, PLATOII, WHO-UNAIDS network). Current H Index is 56.

## Parte C. MÉRITOS MÁS RELEVANTES

### C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores. Si aplica, indique el número de citaciones

- 1 **Artículo científico.** Paraskevi F; Garcia F; Skevaki C. 2023. Update of ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2. Clinica Microbiology and Infection. <https://doi.org/10.1016/j.cmi.2023.04.019>
- 2 **Artículo científico.** Corma-Gómez A; Garcia F. 2023. Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression. Journal of Medical Virology. ISSN 1096-9071. <https://doi.org/10.1002/jmv.28602>
- 3 **Artículo científico.** 2023. Gut Microbiota Composition Can Predict Colonization by Multidrug-Resistant Bacteria in SARS-CoV-2 Patients in Intensive Care Unit: A Pilot Study. Antibiotics (Basel). 12-3, pp.498. ISSN 2079-6382. <https://doi.org/10.3390/antibiotics12030498>
- 4 **Artículo científico.** 2023. Advances in the preclinical characterization of the antimicrobial peptide AS-48. Front Microbiol. <https://doi.org/10.3389/fmicb.2023.1110360>
- 5 **Artículo científico.** 2023. Minocycline Prevents the Development of Key Features of Inflammation and Pain in DSS-induced Colitis in Mice. J Pain. <https://doi.org/10.1016/j.jpain.2022.09.016>
- 6 **Artículo científico.** 2023. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction. Gastroenterol Hepatol. <https://doi.org/10.1016/j.gastrohep.2022.09.009>
- 7 **Artículo científico.** 2023. A call for the comprehensive diagnosis of viral hepatitis as a key step towards its elimination. Liver International. <https://doi.org/10.1111/liv.15529>
- 8 **Artículo científico.** Perez-Florido J; Garcia F. 2023. Detection of High Level of Co-Infection and the Emergence of Novel SARS CoV-2 Delta-Omicron and Omicron-Omicron Recombinants in the Epidemiological Surveillance of Andalusia. Int J Mol Sci. <https://doi.org/10.3390/ijms24032419>
- 9 **Artículo científico.** 2023. Detection and quantification of HBV and HCV in plasma samples by means of different molecular assays: Comparative study. Enfermedades Infecciosas y Microbiología Clínica. <https://doi.org/10.1016/j.eimce.2022.12.007>
- 10 **Artículo científico.** 2023. Synthesis and antimicrobial activity of aminoalkyl resveratrol derivatives inspired by cationic peptides. J Enzyme Inhib Med Chem. <https://doi.org/10.1080/14756366.2022.2146685>
- 11 **Artículo científico.** 2023. The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV/MG molecular assay. Eur J Clin Microbiol Infect.
- 12 **Artículo científico.** Aguilera-Guirao A; Garcia F. 2023. Real-life validation of a sample pooling strategy for screening of hepatitis C. Clin Microbiol Infect. ISSN 1198-743X. <https://doi.org/10.1016/j.cmi.2022.09.006>
- 13 **Artículo científico.** De Salazar A; Garcia F. 2022. Transmitted drug resistance to integrase based first-line HIV antiretroviral regimens in the Mediterranean Europe. Clin Infect Dis. <https://doi.org/10.1093/cid/ciac972>
- 14 **Artículo científico.** 2022. Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Hum Mol Genet. <https://doi.org/10.1093/hmg/ddac158>.

- 15 **Artículo científico.** 2022. Acute severe hepatitis outbreak in children: A perfect storm. What do we know, and what questions remain?. Front Pharmacol. <https://doi.org/10.3389/fphar.2022.1062408>.
- 16 **Artículo científico.** 2022. Novel genes and sex differences in COVID-19 severity. Hum Mol Genet. <https://doi.org/10.1093/hmg/ddac132>.
- 17 **Artículo científico.** 2022. The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome. Biomed Pharmacother. <https://doi.org/10.1016/j.biopha.2022.113445>.
- 18 **Artículo científico.** 2022. Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival. Viruses. <https://doi.org/10.3390/v14091893>.
- 19 **Artículo científico.** 2022. Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe. HIV Med. <https://doi.org/10.1111/hiv.13262>.
- 20 **Artículo científico.** 2022. Ten steps to eliminating hepatitis C in hospitals. Nat Rev Gastroenterol Hepatol. <https://doi.org/10.1038/s41575-022-00647-1>.
- 21 **Artículo científico.** 2022. ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2. Clin Microbiol Infect. <https://doi.org/10.1016/j.cmi.2022.02.011>.
- 22 **Artículo científico.** 2022. The Antioxidant Activity of Thymus serpyllum Extract Protects against the Inflammatory State and Modulates Gut Dysbiosis in Diet-Induced Obesity in Mice. Antioxidants. <https://doi.org/10.3390/antiox11061073>.
- 23 **Artículo científico.** 2022. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV. Clinical Microbiology and Infection. ISSN 1198-743X. <https://doi.org/10.1016/j.cmi.2022.05.018>.
- 24 **Artículo científico.** 2022. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. Journal of Hepatology Reports. <https://doi.org/10.1016/j.jhepr.2022.100462>.
- 25 **Artículo científico.** 2022. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. Journal of Antimicrobial Chemotherapy.
- 26 **Artículo científico.** 2022. HEPATITIS C VIRUS SCREENING AND LINKAGE TO CARE IN MENTAL HEALTH UNITS: AN OPPORTUNITY FOR HCV ELIMINATION. Actas Españolas de Psiquiatría.
- 27 **Artículo científico.** 2022. The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures.
- 28 **Artículo científico.** 2021. Allium-Derived Compound Propyl Propane Thiosulfonate (PTSO) Attenuates Metabolic Alterations in Mice Fed a High-Fat Diet through Its Anti-Inflammatory and Prebiotic Properties.
- 29 **Artículo científico.** Nakanishi T.; Pigazzini S.; Degenhardt F.; et al; Ganna A. 2021. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. Journal of Clinical Investigation. 131. ISSN 00219738. SCOPUS (6) <https://doi.org/10.1172/JCI152386>
- 30 **Artículo científico.** Dietz, Julia; Di Maio, Velia Chiara; de Salazar, Adolfo; et al; German HCV Study Grp. 2021. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. JOURNAL OF HEPATOLOGY. 74. ISSN 0168-8278. <https://doi.org/10.1016/j.jhep.2020.11.017>
- 31 **Artículo científico.** Berenguer J.; García F.; Von-Wichmann M.A. 2021. Guide for the screening of HCV infection in Spain, 2020. Enfermedades Infecciosas y Microbiología Clínica. 39, pp.527-528. ISSN 0213005X. <https://doi.org/10.1016/j.eimc.2020.12.003>
- 32 **Artículo científico.** Aguilera A.; Eiros J.M.; García F. 2021. Impact of COVID-19 pandemic on hepatitis C elimination from the clinical microbiologist perspective. Are we ready?. Enfermedades Infecciosas y Microbiología Clínica. 39, pp.475-476. ISSN 0213005X. <https://doi.org/10.1016/j.eimc.2020.10.011>
- 33 **Artículo científico.** 2021. Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System.
- 34 **Artículo científico.** 2021. SHARED: An International Collaboration to Unravel Hepatitis C Resistance.

- 35 **Artículo científico.** Barrientos-Duran, Antonio; de Salazar, Adolfo; Alvarez-Estevez, Marta; Fuentes-Lopez, Ana; Espadafor, Beatriz; Garcia, Federico. 2020. Detection of sexually transmitted disease-causing pathogens from direct clinical specimens with the multiplex PCR-based STD Direct Flow Chip Kit. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. ISSN 0934-9723.
- 36 Fragkou PC; De Angelis G; Menchinelli G; et al; Skevaki C. 2022. ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. ISSN 1198-743X. <https://doi.org/10.1016/j.cmi.2022.02.011>
- 37 Rossetti B; Fabbiani M; Di Carlo D; et al; EuResist Network, INTEGRATE study group. 2022. Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe. HIV medicine. ISSN 1464-2662. <https://doi.org/10.1111/hiv.13262>
- 38 Fuentes, Ana; Serrano-Conde, Esther; Roldan, Carolina; et al; Garcia, Federico. 2021. Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. ISSN 0934-9723.
- 39 Paz-Graniel, Indira; Babio, Nancy; Becerra-Tomas, Nerea; et al; PREDIMED-Plus Investigators. 2021. Association between coffee consumption and total dietary caffeine intake with cognitive functioning: cross-sectional assessment in an elderly Mediterranean population. EUROPEAN JOURNAL OF NUTRITION. 60. ISSN 1436-6207. WOS (2) <https://doi.org/10.1007/s00394-020-02415-w>
- 40 Barrientos-Duran, Antonio; de Salazar, Adolfo; Fuentes-Lopez, Ana; Serrano-Conde, Esther; Espadafor, Beatriz; Chueca, Natalia; alvarez-Estevez, Marta; Garcia, Federico. 2021. Comparison between Aptima (R) assays (Hologic) and the CoBAS (R) 6800 system (Roche) for the diagnosis of sexually transmitted infections caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. ISSN 0934-9723.
- 41 Ortuno, Francisco M.; Loucera, Carlos; Casimiro-Soriguer, Carlos S.; et al; Dopazo, Joaquin. 2021. Highly accurate whole-genome imputation of SARS-CoV-2 from partial or low-quality sequences. GIGASCIENCE. 10. ISSN 2047-217X. <https://doi.org/10.1093/gigascience/giab078>
- 42 Macias J; Téllez F; de Los Santos I; et al; RIS-HEP20 Study and the HEPAVIR and GEHEP Study Groups. 2021. Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy. Journal of viral hepatitis. 28, pp.878-886. ISSN 1352-0504. <https://doi.org/10.1111/jvh.13496>
- 43 Serrano-Conde E; Leyva A; Fuentes A; et al; García F. 2021. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. Transboundary and emerging diseases. ISSN 1865-1674. <https://doi.org/10.1111/tbed.14417>
- 44 Fernandez-Fuertes, Marta; Corma-Gomez, Anaïs; Torres, Eva; et al; Pineda, Juan A. 2021. Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain after one year of pandemic. TRANSBOUNDARY AND EMERGING DISEASES. ISSN 1865-1674. <https://doi.org/10.1111/tbed.14293>
- 45 Weiner J; Suwalski P; Holtgrewe M; et al; Heidecker B. 2021. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C\*04:01. EclinicalMedicine. 40, pp.101099. Otros (3) <https://doi.org/10.1016/j.eclinm.2021.101099>
- 46 Molina-Tijeras JA; Díez-Echavé P; Vezza T; et al; Gálvez J. 2021. Lactobacillus fermentum CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis. Pharmacological research. 167, pp.105471. ISSN 1043-6618. Otros (5) <https://doi.org/10.1016/j.phrs.2021.105471>
- 47 Crespo, Javier; Lazarus, Jeffrey V.; Iruzubieta, Paula; Garcia, Federico; Garcia-Samaniego, Javier; Alliance Elimination Viral Hepati. 2021. Let's leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world. JOURNAL OF HEPATOLOGY. 75. ISSN 0168-8278. <https://doi.org/10.1016/j.jhep.2021.03.009>

- 48 de Salazar, Adolfo; Barrientos-Duran, Antonio; Espadafor, Beatriz; Fuentes-Lopez, Ana; Chueca, Natalia; García, Federico. 2021. Macrolide and fluoroquinolone resistance of Mycoplasma genitalium in southern Spain, 2018-2019. SEXUALLY TRANSMITTED INFECTIONS. 97. ISSN 1368-4973.
- 49 Aguilera A; Pereira S; Fuentes A; et al; García F. 2021. Pooling samples for hepatitis C RNA detection. The lancet. Gastroenterology & hepatology. 6, pp.608-609. [https://doi.org/10.1016/S2468-1253\(21\)00217-X](https://doi.org/10.1016/S2468-1253(21)00217-X)
- 50 Lopez, Mariana G.; Chiner-Oms, Alvaro; Garcia de Viedma, Dario; et al; SeqCOVID-Spain Consortium. 2021. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. NATURE GENETICS. 53. ISSN 1061-4036. WOS (5) <https://doi.org/10.1038/s41588-021-00936-6>

### C.3. Proyectos y Contratos

- 1 **Proyecto.** Vigilancia epidemiológica de la transmisión de resistencias a antiretrovirales en España. Implementación de una estrategia de estudio de clusters de transmisión en tiempo real.. (FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL - ALEJANDRO OTERO). 01/01/2023-31/12/2025. 56.870 €.
- 2 **Proyecto.** Caracterización de la respuesta de anticuerpos a la vacuna anti-COVID-19 BNT162b2 y sus determinantes. Federico García García. (FIBAO). 01/01/2022-01/01/2025.
- 3 **Proyecto.** Prevalence of HDV infection in Andalusian (Spain) and one-step diagnosis of HBV-HDV. (FIBAO). 01/03/2022-31/03/2023. 50.000 €.
- 4 **Proyecto.** "Programa de Microeliminación de hepatitis C en un centro de inserción social. (FIBAO). 04/03/2022-01/03/2023. 27.161 €.
- 5 **Proyecto.** Hacia la eliminación de la hepatitis C en los pacientes con trastorno mental grave. Ana Fuentes Lopez. (Hospital Universitario San Cecilio). 01/01/2021-31/12/2022. 9.900 €.
- 6 **Proyecto.** Enhancing Whole Genome Sequencing (WGS) and/or Reverse Transcription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the COVID-19 pandemic in the European Union and European Economic Area'. (FIBAO). 01/01/2022-30/09/2022. 350.000 €.
- 7 **Proyecto.** VIGILANCIA EPIDEMIOLOGICA DE LAS RESISTENCIAS PRIMARIAS Y TRANSMITIDAS A LOS ANTIRETROVIRALES EN ESPAÑA. ESTUDIO FILOGENÉTICO, FILODINAMICO Y FILOETNICO.. Federico Garcia Garcia. (Hospital Universitario San Cecilio). 01/01/2019-31/12/2021. 75.020 €.
- 8 **Proyecto.** RED DE SIDA RD 16/002570040. Federico Garcia Garcia. (FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL - ALEJANDRO OTERO). 01/01/2017-31/12/2021. 248.182 €.
- 9 **Proyecto.** Implantación de una aplicación web para la monitorización y caracterización a tiempo real de los clusters con alta tasa de transmisión del VIH en Andalucía Oriental.. Consejería de Salud de la Junta de Andalucía. 2018-2020. 33.100 €. Miembro de equipo.
- 10 **Proyecto.** IMPLEMENTATION OF A NOVEL PLATFORM TO MONITOR TUMOUR HETEROGENEITY AS A CRUCIAL DETERMINANT FOR INDIVIDUALIZED DIAGNOSTIC AND THERAPEUTIC OUTCOME. Juan Antonio Marchal Corrales. (FIBAO). 02/01/2017-31/12/2019. 493.625 €.
- 11 **Proyecto.** PI15/00713, Caracterización virológica de los pacientes que no consiguen Respuesta Viral Sostenida a tratamiento con Antivirales de acción Directa frente al Virus de la Hepatitis C. PROYECTOS INVESTIGACIÓN - AES2015. FEDERICO GARCÍA GARCÍA. (INSTITUTO DE INVESTIGACION BIOSANITARIA DE GRANADA). 01/01/2016-31/12/2018. 121.605 €.
- 12 **Proyecto.** Intensificación de la Actividad Investigadora-Accion A Linea RRHH SAS. Federico Garcia Garcia. (FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL - ALEJANDRO OTERO). 01/01/2017-31/12/2017. 30.000 €.

- 13 Proyecto.** AUTOMATIZACIÓN Y DESARROLLO DE SISTEMAS DE DIAGNÓSTICO MOLECULAR MULTIPLEX PARA DETECCIÓN DE PANELES DE MARCADORES ARN/ADN Y PROTEÍNAS EN LAS ÁREAS DE PATOLOGÍA INFECCIOSA Y ALERGOLOGÍA. CDTI - MINISTERIO DE SANIDAD Y CONSUMO. FEDERICO GARCÍA GARCÍA. (INSTITUTO DE INVESTIGACION BIOSANITARIA DE GRANADA). 01/07/2015-31/12/2017. 34.000 €.
- 14 Proyecto.** PI-0411-2014, Relevancia clínica e impacto económico de la correcta asignación del genotipo/subtipo del Virus de la Hepatitis C en la era de los Antivirales de Acción Directa. MARTA ALVAREZ ESTEVEZ. (HOSPITAL UNIVERSITARIO SAN CECILIO). 01/08/2015-31/07/2017. 27.727 €.
- 15 Proyecto.** Cohorte GEHEP-004. Caracterización virológica y retratamiento de los pacientes que no consiguen RVS a tratamiento con AAD frente al VHC. Federico Garcia Garcia. (FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL - ALEJANDRO OTERO). 01/03/2017-01/04/2017. 14.000 €.
- 16 Proyecto.** Intensificación de la Actividad Investigadora-Acción A Línea RRHH SAS. Federico Garcia Garcia. (FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL - ALEJANDRO OTERO). 01/01/2016-31/12/2016. 30.000 €.
- 17 Proyecto.** INVESTIGACIÓN, DESARROLLO E INNOVACIÓN EN NUEVOS ALIMENTOS MULTIFUNCIONALES PARA SÍNDROME METABÓLICO. BIOSEARCH SL. (INSTITUTO DE INVESTIGACION BIOSANITARIA DE GRANADA). 01/05/2015-31/12/2016. 30.000 €.
- 18 Proyecto.** Intensificación de la Actividad Investigadora-Acción A Línea RRHH SAS. Federico Garcia Garcia. (FUNDACIÓN PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL - ALEJANDRO OTERO). 01/01/2015-31/12/2015. 30.000 €.
- 19 Proyecto.** • ORIGHAMI - ORIGins of Hiv infections Among Migrants; ANRS - 2020-2, ECTZ131727. (FIBAO). Desde 01/07/2021. 36.000 €.
- 20 Contrato.** Clinical evaluation of Seegene's SARS-CoV-2 Variants Assay 01/01/2021-01/01/2022.
- 21 Contrato.** Phenotypic and Site Directed Mutagenesis analysis on the impact of V106I in HIV-1 reverse transcriptase on resistance to Doravirine 09/01/2020-09/01/2022. 75.662 €.
- 22 Contrato.** Integrase baseline resistance: a real-time surveillance program in the MEDIT-RES HIV consortium 01/01/2020-01/01/2022. 147.884 €.
- 23 Contrato.** Point Prevalence of Trichomonas vaginalis and Mycoplasma genitalium over a Broad Geographical Area using the cobas® TV/MG for use on the cobas® 6800/8800 Systems Federico Garcia Garcia. Desde 01/11/2018. 35.000 €.
- 24 Contrato.** A Surveillance Program of Integrase Inhibitors Transmitted Drug Resistance in Spain 02/11/2017-02/07/2018. 55.487 €.

#### **C.4. Actividades de transferencia y explotación de resultados**

Federico Garcia Garcia; Natalia Chueca Porcuna. P12129ES00. Método de obtención de datos útiles para predecir o pronosticar la respuesta al tratamiento antiviral de pacientes con hepatitis C. España. 30/11/2015. Gerencia Provincial del Servicio Andaluz de Salud.